In addition, a study revealed that L3C7c, a high-affinity variant of human sPD-L1, could improve the ability of T cells to inhibit melanoma growth and showed promise as a new-generation tumor immunotherapy agent based on PD-1/PD-L1 axis blockade [174]. Here, SPDL1 is linked to neoplasm.